Loading institutional data...
Loading institutional data...
Insufficient data to determine institutional momentum.
Data as of Q2 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -114%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $8.6M covers the $0 due within a year 8614000.0× over. Scheduled principal only (excludes interest & revolver draws). As of 2025-12-31 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~3.6% on $35.9M of debt.
Cash of $8.6M fully covers short-term debt of $0.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $8.34 today, the market must believe free cash flow compounds -6.4%/yr for a decade (off $8.9M normalized FCF).
The market's -6.4% is more conservative than its 9-yr track record.
2-stage DCF · 0.00B shares · net debt $27.3M
mean 36.6% · volatility σ 537% · implied rate exceeded in 3/7 yrs
Central path = implied -6.4%/yr growth; shaded band = ±1σ (537%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $5.5M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
EOD close · as of 2026-10-02
How a revenue dollar becomes profit — FY2025
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $86.5M 100.0% | $94.1M 100.0% | $112.3M 100.0% | $113.3M 100.0% | $118.9M 100.0% | $102.1M 100.0% | $116.2M 100.0% | $120.8M 100.0% | $77.4M 100.0% | $104.5M 100.0% |
| Cost of Revenue | $36.6M 42.3% | $39.4M 41.8% | $46.2M 41.1% | $52.5M 46.3% | $51.3M 43.1% | $44.1M 43.2% | $51.9M 44.6% | $57.6M 47.7% | $38.2M 49.4% | $56.1M 53.7% |
| Gross Profit | $49.9M 57.7% | $54.8M 58.2% | $66.1M 58.9% | $60.8M 53.7% | $67.7M 56.9% | $58.0M 56.8% | $64.3M 55.4% | $63.2M 52.3% | $39.2M 50.6% | $48.4M 46.3% |
| Research & Development | $8.8M 10.2% | $10.4M 11.1% | $11.8M 10.5% | $12.3M 10.9% | $10.8M 9.1% | $8.7M 8.5% | $10.7M 9.2% | $11.0M 9.1% | $5.6M 7.3% | $5.4M 5.2% |
| Selling, General & Admin | $17.7M 20.5% | $21.5M 22.8% | $22.8M 20.3% | $24.5M 21.6% | $24.3M 20.4% | $23.5M 23.0% | $22.8M 19.6% | $21.4M 17.7% | $17.5M 22.6% | $20.9M 20.0% |
| Total Operating Expenses | $98.5M 113.8% | $61.0M 64.8% | $64.2M 57.2% | $67.8M 59.8% | $65.6M 55.2% | $57.8M 56.6% | $63.9M 55.0% | $62.2M 51.5% | $39.8M 51.4% | $51.4M 49.2% |
| Operating Income | -$48.6M -56.1% | -$6.2M -6.6% | $1.9M 1.7% | -$6.9M -6.1% | $2.1M 1.7% | $221K 0.2% | $377K 0.3% | $984K 0.8% | -$635K -0.8% | -$3.0M -2.9% |
| Interest Expense | $1.3M 1.5% | $800K 0.8% | — | — | — | — | — | $5.4M 4.4% | $713K 0.9% | $639K 0.6% |
| Other Income (Expense), net | -$8.8M -10.2% | -$5.5M -5.8% | -$4.5M -4.0% | -$2.2M -2.0% | -$2.2M -1.9% | -$7.5M -7.4% | -$5.9M -5.1% | -$9.0M -7.4% | -$2.0M -2.6% | -$81K -0.1% |
| Pretax Income | -$57.4M -66.3% | -$11.7M -12.4% | -$2.6M -2.3% | -$9.2M -8.1% | -$140K -0.1% | -$7.3M -7.1% | -$5.5M -4.7% | -$8.0M -6.6% | -$2.6M -3.4% | -$3.1M -2.9% |
| Income Tax Expense | -$686K -0.8% | $740K 0.8% | $859K 0.8% | $337K 0.3% | $148K 0.1% | $518K 0.5% | -$815K -0.7% | -$3.7M -3.0% | -$605K -0.8% | $1.2M 1.2% |
| Net Income | -$56.7M -65.5% | -$12.4M -13.2% | -$3.4M -3.0% | -$9.5M -8.4% | -$288K -0.2% | -$7.8M -7.6% | -$4.7M -4.0% | -$2.9M -2.4% | -$865K -1.1% | -$4.3M -4.1% |
| Per Share | ||||||||||
| EPS (Basic) | $-1.28 | $-0.28 | $-0.08 | $-0.23 | $-0.01 | — | $-0.12 | $-0.08 | $-0.02 | $-0.13 |
| EPS (Diluted) | $-1.28 | $-0.28 | $-0.08 | $-0.23 | — | — | $-0.12 | $-0.08 | $-0.02 | $-0.13 |
| Weighted Avg Shares (Basic) | 44.4M | 43.5M | 42.4M | 41.4M | 40.3M | 38.6M | 37.8M | 36.5M | 34.8M | 34.2M |
| Weighted Avg Shares (Diluted) | 44.4M | 43.5M | 42.4M | 41.4M | 40.3M | 38.6M | 37.8M | 36.5M | 34.8M | 34.2M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-10-02
Where each multiple sits in its own 14-yr range · 7th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
Equity is the year-end figure. On average equity over the two year-ends, ROE is -147.1% — the two diverge when buybacks or issuance move equity during the year.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 47.7 | 44.6 | 43.2 | 43.1 | 46.3 | 41.1 | 41.8 | 42.3 |
| Gross Profit | 52.3 | 55.4 | 56.8 | 56.9 | 53.7 | 58.9 | 58.2 | 57.7 |
| R&D | 9.1 | 9.2 | 8.5 | 9.1 | 10.9 | 10.5 | 11.1 | 10.2 |
| SG&A | 17.7 | 19.6 | 23.0 | 20.4 | 21.6 | 20.3 | 22.8 | 20.5 |
| Operating Income | 0.8 | 0.3 | 0.2 | 1.7 | -6.1 | 1.7 | -6.6 | -56.1 |
| Income Tax | -3.0 | -0.7 | 0.5 | 0.1 | 0.3 | 0.8 | 0.8 | -0.8 |
| Net Income | -2.4 | -4.0 | -7.6 | -0.2 | -8.4 | -3.0 | -13.2 | -65.5 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on HBIO: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Ranked against 1094 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-06-30.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | $1.02T | 49.8× | — | 15.6× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,500 |
| JNJ | $617.0B | 23.2× | 19.6× | 6.5× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | 0.9× | 4,554 |
| ABBV | $464.4B | 111.4× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 3.9× | 4,062 |
| MRK | $356.0B | 19.8× | — | 5.5× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,683 |
| UNH | $333.8B | 28.1× | 19.4× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 2.7× | 3,258 |
| AZN | $243.3B | — | — | — | — | — | — | — | — | — | 1,402 |
| TMO | $242.1B | 36.9× | 31.3× | 5.4× | 3.9% | — | 15.0% | 12.6% | 7.0% | 3.7× | 2,528 |
| AMGN | $217.9B | 28.3× | 18.5× | 5.9× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.2× | 3,070 |
| GILD | $179.5B | 21.4× | 19.7× | 6.1× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,216 |
| ABT | $168.7B | 26.2× | 18.3× | 3.8× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 0.5× | 2,876 |
| PFE | $158.5B | 20.4× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,748 |
| DHR | $150.5B | 42.4× | 31.1× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,050 |
| ISRG | $140.4B | 49.8× | 38.7× | 13.9× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | -0.9× | 2,165 |
| VRTX | $127.9B | 33.0× | 28.0× | 10.7× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | -1.2× | 1,689 |
| BMY | $124.9B | 17.7× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,451 |
| CVS | $110.6B | 62.2× | 11.0× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | -0.9× | 2,009 |
| MDT | $110.5B | 23.2× | 14.5× | 3.0× | 8.4% | 65.0% | 13.2% | 9.7% | 6.2% | 2.8× | 2,050 |
| SYK | $105.6B | 32.8× | 18.2× | 4.2× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 1.8× | 2,183 |
| MCK | $105.2B | 23.5× | 16.6× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 0.4× | 1,943 |
| HCA | $92.4B | 15.1× | — | 1.2× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,288 |
| ELV | $83.8B | 15.3× | 14.4× | 0.4× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 2.9× | 1,560 |
| MRNA | $75.9B | — | — | 39.0× | -39.9% | 55.3% | -145% | -32.6% | -30.5% | — | 774 |
| REGN | $75.7B | 17.7× | 18.1× | 5.3× | 1.0% | — | 31.4% | 14.4% | 13.6% | -0.3× | 1,291 |
| CI | $71.5B | 12.2× | 8.0× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 8.1% | 2.0× | 1,638 |
| BSX | $61.7B | 22.0× | 12.1× | 3.1× | 19.9% | 69.0% | 14.4% | 11.9% | 11.8% | -0.3× | 1,430 |
| HBIO | $38M | — | — | 0.4× | -8.1% | 57.7% | -65.5% | -413% | -114% | — | 2 |
Peers = companies sharing HBIO's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.